Core Insights - ReShape Lifesciences announced the issuance of U.S. Patent 12,350,179 for an intragastric device, enhancing its intellectual property portfolio [1][2] - The patent covers a swallowable capsule with a self-sealing fill valve and a degradable release valve, designed for natural excretion after deflation [1] - The patent protection extends to at least January 2031, potentially longer with a Patent Term Extension [1] Intellectual Property Development - The company has secured over 50 patents related to its intragastric balloon technology since its initial filing in 2011, contributing to a total of over 160 issued and pending patents [2] - This robust patent portfolio positions the company to defend its competitive edge and support its innovation pipeline [2] Company Overview - ReShape Lifesciences specializes in weight loss and metabolic health solutions, offering products like the FDA-approved Lap-Band systems and the non-surgical Obalon balloon technology [3] - The company aims to provide integrated solutions for managing obesity and metabolic diseases [3] Recent Transactions - ReShape has entered into an asset purchase agreement with Biorad Medisys, agreeing to sell substantially all of its assets, including the Lap-Band and Obalon systems [4]

Core Insights - ReShape Lifesciences has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application related to an intragastric balloon system, which includes a swallowable capsule and a degradable release valve designed for natural excretion after deflation [1][2] - The patent, once issued, will provide protection until at least January 2031, potentially extending further with a Patent Term Extension [1] - The company has secured over 50 patents related to its intragastric balloon system since its initial application in 2011, resulting in a total of more than 160 patents issued and pending [2] Company Overview - ReShape Lifesciences is a leading company in the weight loss and metabolic health solutions sector, offering a range of products and services aimed at managing obesity and metabolic diseases [3] - The company’s FDA-approved products include the Lap-Band and Lap-Band 2.0 Flex Systems, which provide minimally invasive treatments for obesity, and the Obalon balloon technology, a non-surgical, swallowable intra-gastric balloon [3] Recent Developments - ReShape Lifesciences has entered into an asset purchase agreement with Biorad Medisys, under which it will sell substantially all of its assets, including the Lap-Band System and Obalon Gastric Balloon System, to Biorad [4]